STOCK TITAN
  1. Home
  2. Sec-filings
  3. OVID
  4. [EFFECT] Ovid Therapeutics Inc. SEC Filing

[EFFECT] Ovid Therapeutics Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: December 22, 2025 4:00 P.M.
Form: S-3
CIK: 0001636651
Company Name: Ovid Therapeutics Inc.
File Number: 333-292151

Source: View Original Filing on SEC EDGAR

Ovid Therapeutics Inc

NASDAQ:OVID

View OVID Stock Overview →

OVID Rankings

#3939 Ranked by Market Cap
N/A Ranked by Dividends
#23 Top Gainer

OVID Latest News

Mar 18, 2026
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
Mar 18, 2026
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
Feb 25, 2026
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Dec 18, 2025
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
Dec 2, 2025
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

OVID Latest SEC Filings

Mar 25, 2026
[Form 4] Ovid Therapeutics Inc. Insider Trading Activity
Mar 18, 2026
[10-K] Ovid Therapeutics Inc. Files Annual Report
Mar 18, 2026
[8-K] Ovid Therapeutics Inc. Reports Material Event
Mar 2, 2026
[Form 4] Ovid Therapeutics Inc. Insider Trading Activity
Mar 2, 2026
[Form 4] Ovid Therapeutics Inc. Insider Trading Activity

OVID Stock Data

318.67M
119.05M
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK